Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Shares of Hims & Hers Health ( HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as ...

As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and ...

(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its ...

Shares of the company were up 8.5% in afternoon trading. The telehealth firm is following its peers Teladoc and LifeMD in offering Lilly's Zepbound ahead of restrictions on selling copies known as ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

A dietitian who went viral on TikTok for easy, healthy recipes shares her favorite ingredients to make high-protein, ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.